| Literature DB >> 34960456 |
Mohammed Jawad Ahmed Alathari1, Yousif Al Mashhadany2, Mohd Hadri Hafiz Mokhtar1, Norhafizah Burham1,3, Mohd Saiful Dzulkefly Bin Zan1, Ahmad Ashrif A Bakar1, Norhana Arsad1.
Abstract
Life was once normal before the first announcement of COVID-19's first case in Wuhan, China, and what was slowly spreading became an overnight worldwide pandemic. Ever since the virus spread at the end of 2019, it has been morphing and rapidly adapting to human nature changes which cause difficult conundrums in the efforts of fighting it. Thus, researchers were steered to investigate the virus in order to contain the outbreak considering its novelty and there being no known cure. In contribution to that, this paper extensively reviewed, compared, and analyzed two main points; SARS-CoV-2 virus transmission in humans and detection methods of COVID-19 in the human body. SARS-CoV-2 human exchange transmission methods reviewed four modes of transmission which are Respiratory Transmission, Fecal-Oral Transmission, Ocular transmission, and Vertical Transmission. The latter point particularly sheds light on the latest discoveries and advancements in the aim of COVID-19 diagnosis and detection of SARS-CoV-2 virus associated with this disease in the human body. The methods in this review paper were classified into two categories which are RNA-based detection including RT-PCR, LAMP, CRISPR, and NGS and secondly, biosensors detection including, electrochemical biosensors, electronic biosensors, piezoelectric biosensors, and optical biosensors.Entities:
Keywords: COVID-19 detection; LAMP; RT-PCR; SARS-CoV-2 detection; biosensor application; coronavirus detection; next generation sequencing (NGS); transmission human exchange
Mesh:
Year: 2021 PMID: 34960456 PMCID: PMC8704003 DOI: 10.3390/s21248362
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1Diverse types of coronaviruses within Nidovirales, Coronaviridae family, Orthocoronavirinae subfamily and the respective genera, (α), (β), (γ) and (δ).
Comparative Coronaviruses that infect the human body respiratory system.
| Coronaviruses | Year of Finding | Emergence | Type | HOST | Cellular Receptor | Incubation Period | Respiratory System Infection | Symptoms | Mortality Rate | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| HCoV-HKU1 | 2005 | Hong Kong | Beta | Human | 9-O-Acetylated sialic acid | 2–4 days | √ | Common cold, Bronchitis, and pneumonia. | N.A. | [ |
| HCoV-Nl63 | 2004 | Holland | Alpha | Human | ACE2 | 2–4 days | √ | Common cold, sore throat, bronchiolitis/croup in children, high temperature, malaise, coughing and rhinitis | N.A. | [ |
| HCoV-229E | 1966 | N.A. | Alpha | Human | Human aminopeptidase N (CD13) | 2–5 days | √ | Common cold, Headache, Fever, Running nose, Pneumonia (in neonates), malaise, Bronchiolitis, | N.A. | [ |
| HCoV-OC43 | 1967 | N.A. | Beta | Human | 9-O-Acetylated sialic acid | 2–5 days | √ | Running nose, Common cold, Fever, Headache, Malaise, Bronchiolitis, Pneumonia (in neonates) | N.A. | [ |
| SARS-CoV | 2002 | Guangdong, southern China | Beta | Civets, Human | ACE2 | 2–11 days | √ | Headache, Diarrhea, Fever, Shivering, Dyspnea, Cough, Pneumonia, Myalgia | 10% | [ |
| MERS-CoV | 2012 | Jeddah, Saudi Arabia | Beta | Camel, Human | DPP4 | 2–14 days | √ | Fever, sore throat, dyspnea, dry cough, Chills, Pneumonia, Myalgia, Diarrhea, Hemoptysis, Headache, Rhinorrhoea | 35% | [ |
| SARS-CoV-2 | 2019 | Hubei province, Wuhan city, China | Beta | Bat, Human | ACE2 | 3–6 days | √ | High body temperature, Short of breath, Headache, Sore throat, myalgia, Dry coughing, Anosmia, rarely pneumonia, Diarrhea, Generalized weakness, Nasal congestion, Rhinorrhea, Sneezing | 2.8% | [ |
| Delta Variant * | 2020 | India | Delta | Human | ACE2 | 5–6 days | √ | Headaches, Sore Throat, Runny Nose, Replacing Cough and Loss of Taste, Loss of Smell | N.A. | [ |
NA = Not Available, * Delta Variant is a mutation of SARS-CoV-2.
Figure 2SARS-CoV and SARS-CoV-2 genomic structure and proteins.
Figure 3Taxonomy of literature reviews on COVID-19 viral virus.
Figure 4COVID-19 respiratory transmission Human-to-Human.
Figure 5Fecal–oral COVID-19 transmission.
Human exchange transmission comparison.
| Comparison | Transmission Human Exchange | |||
|---|---|---|---|---|
| Respiratory Transmission | Fecal–Oral Transmission | Ocular Transmission | Vertical Transmission | |
| Probability | More likely | More likely | Less likely | Less likely |
| Possibility | High | High | Rare | Rarer |
| Confirmed Cases | Confirmed | Confirmed | Confirmed | Unconfirmed |
| Virus entry organ | Mouth, Nose | Mouth | Eye | Uterus |
| Transmissibility approach | Direct, Indirect | Indirect | Direct, Indirect | Direct |
| Genus | Male and Female | Male and Female | Male and Female | Female |
RNA Coronavirus detection methods analysis based on RT-PCR, LAMP, NGS and CRISPR.
| Reference | Coronavirus | Analyte | Target Genes | Detection Methods | Limit of Detection | Concentration | Detection Time | Tested Sample |
|---|---|---|---|---|---|---|---|---|
| [ | SARS-CoV | RNA | Polymerase | RT-PCR | 10 copies/reaction | N.A. | (5) h | Nasal aspirate |
| [ | SARS-CoV | RNA | NA | RT-PCR | 2 nM | N.A. | (~2) h | Throat swab samples |
| [ | MERS-CoV | RNA | (N) gene | rRT-PCR | 10 copies/reaction or 0.0013 TCID50/ml | 10–108 copies/-reaction | (~2) h | Serum, nasopharyngeal/- oropharyngeal swab, and sputum samples |
| [ | COVID-19 | RNA | (E)-gene | rRT-PCR | 275.7 copies/reaction | N.A. | (~1) h | Swab samples |
| [ | COVID-19 | RNA | (N) gene | rRT-PCR | 10 copies/reaction | N.A. | (~30) min | Plasmids containing the complete N gene |
| [ | MERS-CoV | RNA | (N) gene | RT-LAMP | 10 copies/μL | 5 × 101–5 × 108 copies/-reaction | (35) min | Throat swab specimens |
| [ | SARS-CoV | RNA | (ORF1b) and (N) gene | LAMP | 104 copies/reaction | N.A. | (20–25) min | Synthetic RNA solutions |
| [ | COVID-19 | RNA | (ORF1b) and (N) gene | RT-LAMP | 20 copies/reaction | N.A. | (20–30) min | Nasopharyngeal swab and bronchoalveolar lavage fluid samples |
| [ | COVID-19 | RNA | (ORF1ab), (N) and (E) gene | RT-LAMP | 5 copies/reaction | N.A. | (30) min | Nasopharyngeal swab specimens |
| [ | COVID-19 | RNA | (S) gene | NGS | 125 GCE/mL | N.A. | N.A. | Nasopharyngeal swab |
| [ | COVID-19 | RNA | (N) and (E) gene | CRISPR/Cas13a | ~100 copies/µL | 3.2 × 105 –1.65 × 103 copies/µL | (30) min | Nasal swab |
NA = NOT available, N = nucleocapsid, E = envelope, ORF1b = open reading frame 1b, S = s pike protein.
Coronavirus detection methods analysis based on biosensor application.
| Reference | Publication Year | Coronavirus | Biosensor Detection Technique | Material | Target | Detection Time | Linear Range | Tested Sample | Limit of Detection | Temperatures |
|---|---|---|---|---|---|---|---|---|---|---|
| [ | 2 April 2021 | COVID-19 | Electrochemical | (PANI) | N gene | 1 h | 10−14 to 10−9 M | NR | 3.5 fM | 37 °C |
| [ | 11 May 2020 | COVID-19 | Electrochemical | Gold | S protein | 10–30 s | 1 fM to 1 μM | Spiked saliva samples | 90 fM | 4 °C |
| [ | 27 February 2019 | MERS-CoV | Electrochemical | Gold | S protein | 20 min | 1 pg·mL−1 to 10 μg·mL−1 | Spiked nasal samples | 0.4 and 1.0 pg·mL−1 | RT |
| [ | 15 April 2020 | COVID-19 | Electrical (FET) | Graphene | S protein | 4 h | NR | nasopharyngeal swab | 1.6 × 101 pfu/mL | NR |
| [ | 2020 | COVID-19 | Electrical (FET) | Graphene | S protein | 2 min | NR | Spiked spike protein solutions | 0.2 pM | NR |
| [ | 1 July 2004 | SARS-CoV | Piezoelectric | Crystal with quartz wafer | Antigen sputum | 1 h | 1–4 µg/µL | NR | 0.60 mg/mL | RT |
| [ | 13 March 2020 | COVID-19 | Optical (fluorescence) | Not Specified | N protein | 10 min | NR | Nasopharyngeal aspirate swabs and urine | Not Specified | NR |
| [ | 14 August 2021 | COVID-19 | Optical (fluorescence) | Not Specified | IgG | 25 min | NR | Human serum | 12.5 ng/mL | NR |
| [ | 11August 2021 | SARS-CoV-2 | Optical (SPR) | Nb2C-SH QD | N gene | NA | 0.05 to 100 ng·mL−1 | Human serum | 4.9 pg·mL−1 | NR |
| [ | 17 July 2009 | SARS-CoV | Optical (LSPCF) | polymethyl methacrylate | N protein | 2 h | 0.1 pg/mL to 1 ng/mL | Human serum | ∼1 pg/mL | 37 °C |
| [ | 1 September 2021 | COVID-19 | Optical (P-FAB) | Gold nanoparticles | N protein | 10 min | 0.1 ng/mL and 100 ng/mL | PBS Buffer | ~2.5 ng/mL | NR |
Electropolymerized polyaniline (PANI) nanowires, (G/SPCE) = A graphene-modified screen-printed carbon electrode, RT = Room Temperature, (P-FAB) = plasmonic fiber optic absorbance biosensor, NR = Not Reported, N = nucleocapsid, S = spike protein.
COVID-19 detection techniques advantages and limitations comparison.
| Categories of Coronavirus Detection | Techniques | Advantages | Limitation |
|---|---|---|---|
| Indirect detection RNA | RT-PCR |
❖ Reliable/detects current viral infection ❖ Rapid results ❖ Higher sensitivity ❖ Needs a slight amount of DNA ❖ It can be performed in a single step ❖ Well established methodology in viral diagnostics |
❖ Inability to detect already recovered patients. ❖ Depends on Spiked-in material. ❖ Requires sophisticated instruments. ❖ Low sensitivity. ❖ The need to extract RNA. ❖ Higher costs due to expensive consumables usage. ❖ Complex detection. |
| Indirect detection RNA | LAMP |
❖ Extremely repeatable ❖ Precise ❖ One working temperature (60–65°) ❖ Rapid reaction ❖ Accurate ❖ Fast amplification ❖ Operation Simplicity ❖ Detection Simplicity |
❖ Low versatility ❖ Possibility of primer–primer interactions ❖ Low detection sensitivity. ❖ Long detection time. ❖ The need to extract RNA from clinical samples. ❖ Cannot detect recovered patients. ❖ Too sensitive, highly susceptible to false ❖ positives due to carry-over or cross-contamination |
| Indirect detection RNA | NGS |
❖ Highly sensitive ❖ Specific ❖ Can identify the novel strain |
❖ Slow detection. ❖ The need to extract RNA from clinical samples. ❖ High expertise required ❖ Equipment dependency ❖ Expensive ❖ Requires highly sophisticated Lab ❖ Unable to detect recovered patients. |
| Indirect detection RNA | CRISPR |
❖ Affordable ❖ High detection speed ❖ High sensitivity |
❖ Several CRISPR-based kits are still in development phase ❖ Clinical validation is required ❖ Not yet widespread and in clinical trials |
| Indirect detection: Spike (S) and Nucleocapsid (N) proteins | Electrochemical sensors |
❖ Structure simplicity ❖ High-level sensitivity ❖ Economical ❖ Instant response ❖ Label-Free |
❖ High need for kits. ❖ Tiresome sample collection. ❖ Time-consuming process ❖ Requires trained personnel ❖ Requires adequate laboratory infrastructure |
| Indirect detection: Spike (S) protein | Electronic sensors(FET) |
❖ Low cost ❖ High speed ❖ Small size ❖ Excellent compatibility with integrated circuits (ICs). |
❖ The signal transduction process found is not always apparent. ❖ Heterogeneous interface structures. ❖ Long time result. |
| Indirect detection: Antigen sputum | Piezoelectric sensor |
❖ Rapid ❖ Highly sensitive ❖ Specific ❖ Label-free |
❖ Depends on sample preparation ❖ Complex pretreatment steps |
| Indirect detection: IgM antibody and Nucleocapsid (N) Protein | Optical (fluorescence, SPR, LSPCF, and P-FAB) |
❖ Rapid ❖ Sensitive ❖ Specific |
❖ Requirement for point of care remains difficult. ❖ High cost. |